These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 18989671

  • 1. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.
    Clin Cancer Res; 2009 May 15; 15(10):3633-9. PubMed ID: 19401344
    [Abstract] [Full Text] [Related]

  • 4. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD, Tran HT, Riggs MW.
    Cancer Chemother Pharmacol; 2006 Jan 15; 57(2):241-7. PubMed ID: 16133538
    [Abstract] [Full Text] [Related]

  • 5. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
    Kaag D.
    Lung Cancer; 2013 Jan 15; 79(1):54-8. PubMed ID: 23131495
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, Hartmann JT.
    Cancer Chemother Pharmacol; 2011 Sep 15; 68(3):693-701. PubMed ID: 21136060
    [Abstract] [Full Text] [Related]

  • 7. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I.
    Gynecol Oncol; 2005 Nov 15; 99(2):327-33. PubMed ID: 16005943
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC.
    Gynecol Oncol; 2006 Dec 15; 103(3):1063-9. PubMed ID: 16875719
    [Abstract] [Full Text] [Related]

  • 9. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Dec 15; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 10. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge ME, Mathôt RA, Van Dam SM, Beijnen JH, Rodenhuis S.
    Cancer Chemother Pharmacol; 2002 Sep 15; 50(3):251-5. PubMed ID: 12203108
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of high-dose carboplatin in children and adults.
    Lindauer A, Eickhoff C, Kloft C, Jaehde U.
    Ther Drug Monit; 2010 Apr 15; 32(2):159-68. PubMed ID: 20110851
    [Abstract] [Full Text] [Related]

  • 12. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.
    Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ.
    J Oncol Pharm Pract; 2012 Sep 15; 18(3):323-32. PubMed ID: 22331238
    [Abstract] [Full Text] [Related]

  • 13. [Estimating renal function based on creatinine clearance: application of different formulas and correction for obese patients].
    Apperloo JJ, Gerlag PG, Beerenhout CH, Vader HL.
    Ned Tijdschr Geneeskd; 2007 May 05; 151(18):1016-23. PubMed ID: 17508688
    [Abstract] [Full Text] [Related]

  • 14. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
    Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA.
    Gynecol Oncol; 2008 Jun 05; 109(3):353-8. PubMed ID: 18407341
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep 05; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 16. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.
    Winter MA, Guhr KN, Berg GM.
    Pharmacotherapy; 2012 Jul 05; 32(7):604-12. PubMed ID: 22576791
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of carboplatin in children.
    Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roché H, Robert A, Newell DR, Canal P.
    Clin Pharmacol Ther; 1996 Apr 05; 59(4):436-43. PubMed ID: 8612389
    [Abstract] [Full Text] [Related]

  • 18. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.
    Cancer Chemother Pharmacol; 2001 May 05; 47(5):373-9. PubMed ID: 11391850
    [Abstract] [Full Text] [Related]

  • 19. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults.
    Park EJ, Pai MP, Dong T, Zhang J, Ko CW, Lawrence J, Crentsil V, Zhang L, Xu NN.
    Ann Pharmacother; 2012 Mar 05; 46(3):317-28. PubMed ID: 22395245
    [Abstract] [Full Text] [Related]

  • 20. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease.
    Golik MV, Lawrence KR.
    Pharmacotherapy; 2008 Sep 05; 28(9):1125-32. PubMed ID: 18752383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.